Novici Biotech LLC

Other

Large Scale Biology Corporation

Musc Foundation for Research Development

Ibio Limited

Hal S Padgett

John A Lindbo

Wayne P Fitzmaurice

Andrew A Vaewhongs

Fakhrieh S Vojdani

Carol A Feghali-Bostwick

Terence E Ryan

Matthew McGee

Mark L Smith

Gregory P Pogue

R Barry Holtz

Matthew Mcgee

Carol Feghali-Bostwick

Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.

Endostatin fragments and variants for use in treating fibrosis

This document provides materials and methods for producing endostatin fusion polypeptides having anti-fibrotic activity. For example, provided herein are fusion polypeptides having an IgG Fc domain and a portion of human endostatin that can form high molecular weight multimers, as well as methods for producing such fusion polypeptides in plant cells.

Materials and methods for producing endostatin fusion polypeptides in plant cells

Methods to derive novel hybrid type 1 interferons that are broadly active against highly pathogenic viruses of biodefense significance are described. Libraries of hybrid interferon genes were produced using gene shuffling, the proteins were expressed, and screened for activity against viruses of interest. Sequences of several broadly active hybrid interferons are described.

Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity

Described is a method of screening libraries of variant proteins produced in plant leaves using a plant viral vector to identify a gene of interest comprising, inoculating leaves with a library of viruses expressing variant genes, allowing time for infected foci to form, harvesting a leaf, sticking one face of the leaf to a sticky support material to immobilize the leaf and leaving the opposing face of the leaf exposed, abrading the exposed face with granular material, placing the abraded face in contact with a blot membrane having a backing comprising blotting paper, placing the assembly into a vacuum seal bag; evacuating and sealing the bag; removing the assembly and separating the membrane, performing an assay on the membrane to identify an infected focus of interest; recovering virus corresponding to the infected focus; recovering nucleic acid from the virus, and identifying the gene of interest from the nucleic acid.

Laminar library screen

Herein is described a modified viral vector comprising: a coat protein modified, for example by the addition of a cysteine residue, such that the modified viral vector yields less soluble virus relative to that from an unmodified viral vector upon extraction of plant material infected with the modified viral vector, thereby facilitating purification of a recombinant protein expressed from the modified viral vector. Also described is a method of reducing viral coat protein impurities during purification of a recombinant protein, a method of biocontainment for a recombinant viral vector, and a method of generating virus inoculum for the modified viral vector.

Virus coat protein variants with self-subtracting properties

Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.

Interferon alpha and interferon kappa fusion protein

We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3' to 5&#x2032; exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.

Method of increasing complementarity in a heteroduplex

We describe here an in vitro method of redistributing sequence variations between non-identical polynucleotide sequences, by making a heteroduplex polynucleotide from two non-identical polynucleotides; introducing a nick in one strand at or near a base pair mismatch site; removing mismatched base(s) from the mismatch site where the nick occurred; and using the opposite strand as template to replace the removed base(s) with bases that complement base(s) in the first strand. By this method, information is transferred from one strand to the other at sites of mismatch.

Population of polynucleotide sequence variants

Nucleic acid molecules encoding endonucleases and methods of use thereof

We describe here restriction endonucleases and their uses. Restriction endonucleases are useful in finding single nucleotide polymorphisms. They are also useful in an in vitro method of redistributing sequence variations between non-identical polynucleotide sequences.

Growing community of inventors

Vacaville, CA, United States of America

Hal S Padgett